Exhibit 10.80
​
[REDACTED] = Pursuant to Item 601(b)(10) of Regulation S-K, portions of this exhibit have been omitted as the registrant has determined that certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
​
​
TERMINATION AGREEMENT
On January 20, 2021, Aytu BioScience, Inc., now Aytu BioPharma, Inc., a Delaware corporation with offices at 373 Inverness Pkwy, Suite 206, Englewood, CO 80112 (“AYTU”), and Avrio Genetics, LLC, a Commonwealth of Pennsylvania limited liability corporation with offices at 3467 Trexler Blvd, Allentown, PA 18104 (“Licensee”) entered into an Exclusive License Agreement (“Agreement”) relating to the Patent Rights, Trademark Rights and Technical Information, as defined therein.
On February 4, 2021, Aytu and Licensee agreed to amend the Agreement by entering into a First Amendment to Exclusive License Agreement. On March 4, 2021, Aytu and Licensee agreed to further amend the Agreement by entering into a Second Amendment to Exclusive License Agreement.
AYTU and Licensee now wish to terminate the Agreement.
By mutual agreement, evidenced by this signed Termination Agreement, AYTU and Licensee terminate the Agreement pursuant to the terms of Section 7.2(f). The date of termination shall be: June 29, 2021.
Pursuant to the terms of the Agreement, Licensee shall pay the royalties, cost for inventory, original shipping fees, and patent fees as described in Appendix A.
Aytu shall arrange for a courier to pick up the inventory as described in Appendix B, on July 2, 2021.
Licensee acknowledges that Aytu shall assume responsibility for inventory produced by LasX, approximately [REDACTED] sensors, and Aytu acknowledges that Licensee may sell any other currently held, or returned inventory, in accordance with Section 7.3.
Both AYTU and Licensee acknowledge and agree that the terms of Sections 7.3, 7.5, 7.6 and 7.7 of the Agreement shall survive termination.
Acknowledged and agreed, effective as of the date written above:
	LICENSEE: 
	​

	Avrio Genetics, LLC
	​

	​
	​

	​
	​

	By:
	​
	​

	Name: 
	Brandon Hensinger
	​

	Title:
	CEO
	​



​
​



​
	​
	​

	AYTU:
	​

	Aytu BioPharma, Inc.
	​

	​
	​

	​
	​

	By:
	​
	​

	Name: 
	Joshua Disbrow
	​

	Title:
	Chief Executive Officer
	​



​

2



[REDACTED] = Pursuant to Item 601(b)(10) of Regulation S-K, portions of this exhibit have been omitted as the registrant has determined that certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
​
​
APPENDIX A
FEES DUE
​
​
	
	AYTU BioPharma, Inc.
373 Inverness Parkway
Suite 206
Englewood, CO 80112
Phone:  (720) 437-6580
Fax:
	​
	INVOICE

	​
	​
	Invoice No.
	06292021

	​
	​
	Date
	06/29/2021

	​
	​
	Order No.
	​

	​
	​
	Shipper ID
	​

	​
	​
	Order Type
	Invoice

	​
	​
	Customer ID
	AVRIOGENET



​
	BILL TO:
	SHIP TO:

	Avrio Genetics
[REDACTED]
​
	Avrio Genetics
[REDACTED]



​
PAGE 1
	F.O.B. POINT
	SHIP VIA
	ORDERED BY
	CUSTOMER P.O. NO.

	​
	​
	​
	​

	ORDER DATE
	TERMS
	SALES PERSON
	SITE

	6/29/021
	[REDACTED]
	​
	HOMEOFFICE
Home Office - Englewood

	PART NUMBER
	QTY ORDERED
	UNITS
	QTY SHIPPED
	QTY BO
	PRICE
	DISC %
	EXT. PRICE

	00001

	
-

[REDACTED] for royalties




-

[REDACTED] for sold inventory




-

[REDACTED]  for patent fees




-

[REDACTED] shipping fees




-

[REDACTED] Sensors
Total due: [REDACTED]



Payment schedule: Twelve (12) equal installment payments in the amount of [REDACTED]  due by the 1st of each month, starting August 1, 2021.  [REDACTED] late fee for any payment not received by the 3rd day of each month.

	Please remit payment to:
Wells Fargo Bank N.A.
ACH Payments:
Routing: [REDACTED]
Account: [REDACTED]
Wire Payments:
Routing: [REDACTED]
Account: [REDACTED]
SWIFT/BIC Code for USD payments: [REDACTED]
	Sales Total
	[REDACTED]

	​
	Shipping & Handling
	​

	​
	Misc. Charges
	[REDACTED] 

	​
	Tax Total
	[REDACTED] 

	​
	​
	[REDACTED] 

	​
	Less Paid Amount
	[REDACTED] 

	​
	TOTAL
	[REDACTED]



​
​
​

​



[REDACTED] = Pursuant to Item 601(b)(10) of Regulation S-K, portions of this exhibit have been omitted as the registrant has determined that certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
​
​
APPENDIX B
INVENTORY TO BE REPOSSESSED
[REDACTED]

​